达比加群酯的临床药理及其预防心房颤动患者卒中的研究进展

Dabigatran etexilate,a novel oral anticoagulant for stroke prevention in patients with atrial fibrillation

达比加群酯是近几年上市的一种新型口服抗凝药物,最初用于预防关节置换术后血栓的形成。美国FDA于2010年10月批准达比加群酯用于预防心房颤动患者的脑卒中。本文对其药理作用、药代动力学、临床疗效评价及不良反应等做一综述。

Dabigatran etexilate,a novel oral direct thrombin inhibitor that was firstly used in preventing venous thrombo-embolism after arthroplasty,has been proved by the American Food and Drug Administration（FDA） for stroke prevention in patients with atrial fibrillation in October 2010.In this paper,we reviewed the pharmacology,pharmacokinetics,clinical efficacy and safety of dabigatran etexilate.